About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Neutralizing Power of Serum Antibodies - 2 | Clinical Trials | Clareo Health

Back to clinical trial search

RECRUITINGNANCT07085611

Neutralizing Power of Serum Antibodies - 2

Severe forms of COVID-19 and Monkeypox affect immunocompromised and comorbid individuals. Vaccination and monoclonal antibody therapies induce neutralizing antibodies. This neutralizing power is recog...

Lead sponsor: Centre Hospitalier Régional d'Orléans•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Thierry PRAZUCK, Dr

CONTACT

0238229593 thierry.prazuck@chu-orleans.fr

Sponsors

Lead Sponsor

Centre Hospitalier Régional d'Orléans

This is a monocentric, longitudinal, descriptive study aiming to measure and describe the evolution of the humoral immune response (serum and nasal) to SARS-CoV-2 and MPXV, following any vaccination or administration of monoclonal antibodies. Samples are collected over a maximum 60-month period per participant to assess the durability of neutralizing activity.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Adults (≥18 years)
•Patients receiving or scheduled to receive anti-SARS-CoV-2 and/or anti-MPXV vaccines or monoclonal antibodies
•Patients have provided written informed consent

Exclusion Criteria

•Persons under guardianship or curatorship
•Persons under legal protection,
•Persons persons deprived of liberty
•Persons not affiliated to a social security scheme
•Pregnant or breastfeeding women

Related studies

Viral Infections in Healthy and Immunocompromised Hosts

NCT01306084 · Anogenital Herpes, COVID-19, and more

The Effect of COVID-19 Pandemic on Adolescent and Young Adult Cancer Patients and Survivors

NCT04551378 · COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, and more

REmotely Monitored, Mobile Health Supported Multidomain Rehabilitation Program With High Intensity Interval Training for COVID-19

NCT05218083 · COVID-19, Critical Illness, and more

Vaccine Responses to SARS-CoV-2 and Other Emerging Infectious Diseases

NCT05078905 · COVID-19, Vaccination, and more

RECRUITINGPhase 1

A Study of How Ibuzatrelvir is Taken up Into the Blood of Healthy Adults After Taking Different Tablets of Ibuzatrelvir

NCT07552779 · Coronavirus Disease 2019, Coronavirus Disease 2019 (COVID-19), and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 19, 2025Terms

Trial snapshot

StatusRECRUITING

PhaseNA

Enrollment30

Start dateAug 2025

Last updatedDec 19, 2025

Condition

COVID-19 SARS-CoV-2 Viraemia Monkey Pox Vaccination Serum+1 more

Locations shown

CHU Orléans

Orléans

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 19, 2025Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions